-
公开(公告)号：US20220089704A1
公开(公告)日：2022-03-24
申请号：US17288445
申请日：2019-10-28
Applicant: Biogen MA Inc. , National Research Council of Canada
Inventor： Benjamin A. Smith , Andreas Lehmann , Thomas O. Cameron , R. Blake Pepinsky , Dingyi Wen , Graham K. Farrington , Gopalan Raghunathan , Nels E. Pederson , Danica Stanimirovic , Traian Sulea , Arsalan S. Haqqani
Abstract: Featured are compositions comprising humanized and engineered variants of an antibody variable domain (e.g., FC5), chimeric molecules comprising same, compositions comprising same, and uses thereof.
-
Patent Agency Ranking
公开(公告)号：US20160159878A1
公开(公告)日：2016-06-09
申请号：US14952613
申请日：2015-11-25
Applicant: Biogen MA Inc.
Inventor： Daniel H.S. Lee , Dingyi Wen , R. Blake Pepinsky , Jane K. Relton , Xinzhong Wang , Alexey Lugovskoy , Werner Meier , Ellen A. Garber , Laura Silvian , Paul H. Weinreb
IPC: C07K14/705
CPC classification number: C07K14/705 , A01K67/027 , A01K67/0275 , A01K2217/058 , A01K2227/105 , A01K2267/0356 , A61K38/179 , A61K39/3955 , A61K48/00 , A61K2039/505 , C07K16/28 , C07K16/2863 , C07K2317/34 , C07K2317/55 , C07K2317/56 , C07K2317/76 , C07K2319/30 , C07K2319/32 , C07K2319/33 , C07K2319/74 , C12N15/1136 , C12N15/1138 , C12N15/8509 , C12N2310/111 , C12N2310/14 , C12N2310/53
Abstract: Disclosed are immunogenic Nogo receptor-1 polypeptides, Nogo receptor-1 antibodies, antigen-binding fragments thereof, soluble Nogo receptors and fusion proteins thereof and nucleic acids encoding the same. Also disclosed are Nogo receptor antagonist polynucleotides. Also disclosed are compositions comprising, and methods for making and using, such Nogo receptor antibodies, antigen-binding fragments thereof, soluble Nogo receptors and fusion proteins thereof, nucleic acids encoding the same and antagonist polynucleotides.
Abstract translation: 公开了免疫原性Nogo受体-1多肽，Nogo受体-1抗体，其抗原结合片段，可溶性Nogo受体及其融合蛋白和编码其的核酸。 还公开了Nogo受体拮抗剂多核苷酸。 还公开了包含这样的Nogo受体抗体，其抗原结合片段，可溶性Nogo受体及其融合蛋白，编码相同的核苷酸和拮抗剂多核苷酸的制备和使用方法。
-
公开(公告)号：US20150274808A1
公开(公告)日：2015-10-01
申请号：US14638215
申请日：2015-03-04
Applicant: BIOGEN MA INC.
Inventor： David Evans , R. Blake Pepinsky , Dingyi Wen , Rashmi Rohit Kshirsagar , Karin Lucas
IPC: C07K16/00
CPC classification number: C07K16/00 , C07K1/1133
Abstract: The present invention pertains to methods of preventing and eliminating trisulfide bonds in proteins such as antibodies. In one embodiment, trisulfide bonds in proteins are converted to disulfide bonds as part of chromatographic purification procedures. In another embodiment, the formation of trisulfide bonds in proteins is inhibited by implementation of methods described herein during the cell culture production of such proteins. In another embodiment, monoclonal antibodies are produced by the methods described herein.
Abstract translation: 本发明涉及在蛋白质如抗体中预防和消除三硫键的方法。 在一个实施方案中，作为色谱纯化方法的一部分，将蛋白质中的三硫键转化为二硫键。 在另一个实施方案中，通过在这些蛋白质的细胞培养生产期间实施本文所述的方法来抑制蛋白质中三硫键的形成。 在另一个实施方案中，通过本文所述的方法产生单克隆抗体。
-
公开(公告)号：US20220348623A1
公开(公告)日：2022-11-03
申请号：US17541765
申请日：2021-12-03
Applicant: Biogen MA Inc.
Inventor： R. Blake Pepinsky , Andreas Lehmann , Dingyi Wen
Abstract: Methods of activating GDF11 proteins in vitro as well as formulations of mature GDF11 polypeptides with enhanced solubility at neutral pH are provided.
-
公开(公告)号：US20200031895A1
公开(公告)日：2020-01-30
申请号：US16468347
申请日：2017-12-15
Applicant: Biogen MA Inc.
Inventor： R. Blake Pepinsky , Andreas Lehmann , Dingyi Wen
Abstract: Methods of activating GDF11 proteins in vitro as well as formulations of mature GDF11 polypeptides with enhanced solubility at neutral pH are provided.
-
公开(公告)号：US10308706B2
公开(公告)日：2019-06-04
申请号：US14638215
申请日：2015-03-04
Applicant: BIOGEN MA INC.
Inventor： David Evans , R. Blake Pepinsky , Dingyi Wen , Rashmi Rohit Kshirsagar , Karin Lucas
Abstract: The present invention pertains to methods of preventing and eliminating trisulfide bonds in proteins such as antibodies. In one embodiment, trisulfide bonds in proteins are converted to disulfide bonds as part of chromatographic purification procedures. In another embodiment, the formation of trisulfide bonds in proteins is inhibited by implementation of methods described herein during the cell culture production of such proteins. In another embodiment, monoclonal antibodies are produced by the methods described herein.
-
-
-
-
-
Search Results
6
records
(took 0.022 seconds)
